Home>Topics>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical BMRN

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Cramer's Mad Money - Where Did The Investors Go? (9/8/14)

      Headlines

      Tue, 9 Sep 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday September 8. Where Did The Investors Go? General Mills (NYSE: GIS ), Annie's (NYSE: BNNY ), Hain Celestial (NASDAQ: HAIN ), Mobileye (NYSE: MBLY ), GoPro (NASDAQ: GPRO ), Bob Evans

    2. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      remained a frequent flier whenever an analyst or writer has wanted to write up a story on potential biotech/pharma M&A - Roche has been tied to Alexion (NASDAQ: ALXN ), BioMarin (NASDAQ: BMRN ), and Chugai on the more Complete Story »

    3. New Morningstar Analyst Report for Biomarin Pharmaceutical Inc

      Stock Reports

      Tue, 5 Aug 2014

      Accurate diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing scale-up costs.BioMarin's newest Phase III drug candidates could have high hurdles for approval; Pompe disease drug BMN 701 is going

    4. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals BMRN 185 0.07 Matt's Roth IRA: Corcept Therapeutics CORT 108 0.04 N/A Matt's Roth IRA: Cyberonics CYBX $179 0.07 N

    5. Slightly Lowering BioMarin's Fair Value After Peg-Pal Delay, but Stock Remains Undervalued

      Commentary

      Fri, 2 May 2014

      Pal because of the redesign of its Phase III trial, and we've also pushed back the launches of other late stage candidates BMRN -673 and BMN-701, as we have factored delayed starts and longer enrollment periods into our analysis. Given the heavy investment

    6. Our Outlook for Health-Care Stocks

      Headlines

      Fri, 28 Jun 2013

      attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX, Regeneron REGN, Incyte INCY, Biomarin BMRN , and Seattle Genetics SGEN. Valeant VRX made the biggest acquisition splash over the past few months, acquiring Bausch & Lomb

    7. Raising Our BioMarin Fair Value Estimate Based on Positive Long-Term Outlook

      Commentary

      Mon, 6 May 2013

      We're raising our fair value estimate for BioMarin BMRN to $71 per share from $59, after reassessing our long-term growth assumptions for the firm. Specifically, we have boosted

    8. From Barron’s, April 29, 2013 (Part 2)

      Commentary

      Sat, 27 Apr 2013

      premium as the related biotech research has finally become more productive and fruitful. Mentioned are PFE, BMY, LLY, BIIB, BMRN . http://online.barrons.com/article/SB50001424052748703889404578438831955549290.html?mod=BOL_twm_col

    9. BioMarin's 1Q Fundamentals Are Strong; Late-Stage Pipeline Supports Positive Moat Trend

      Commentary

      Thu, 25 Apr 2013

      BioMarin BMRN reported first-quarter results that were in line with our expectations, and we're maintaining our $59 per share fair value

    10. Our Outlook for Health-Care Stocks

      Headlines

      Fri, 29 Mar 2013

      attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX, Regeneron REGN, Incyte INCY, Biomarin BMRN , and Seattle Genetics SGEN. Top Health-Care Sector Picks Star Rating Fair Value Estimate Economic Moat Fair Value Uncertainty

    « Prev12345Next »
    Content Partners